Eric D. Donnelly
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Eric D. Donnelly

Radiation Oncology
251 E Huron St Ste LC-178, Galter Pavilion, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
19 Years of Experience
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
251 E Huron St Ste LC-178, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eric Donnelly is a Radiation Oncologist in Chicago, Illinois. Dr. Donnelly has been practicing medicine for over 19 years and is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Breast Cancer, Endometrial Cancer, Vulvar Cancer, and Mycosis Fungoides.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
St Louis University School Of Medicine, 2006
Residency
McGaw Medical Center of Northwestern University
Specialties
Radiation Oncology
Licenses
Radiology in IL
Board Certifications
American Board Of Radiology - Radiation Oncology (Certified)
American Board Of Orthopaedic Surgery - Orthopaedic Surgery (Certified)
Hospital Affiliations
Northwestern Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

251 E Huron St Ste LC-178, Galter Pavilion, Chicago, IL 60611

Additional Areas of Focus

Dr. Donnelly has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Device, Other
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Olaparib
Study Phase: Phase 2
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery
Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Radiation, Other
Study Phase: Not Applicable
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
View 7 Less Clinical Trials

45 Total Publications

Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Journal: Gynecologic oncology
Published: January 05, 2025
Similar Doctors
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Matthew Koshy
Radiation Oncology
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Matthew Koshy
Radiation Oncology

The University Of Chicago

5841 S Maryland Ave, 
Chicago, IL 
 (7.4 miles away)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Koshy is a Radiation Oncologist in Chicago, Illinois. Dr. Koshy is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Astrocytoma, and Glossectomy. Dr. Koshy is currently accepting new patients.

Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Ralph R. Weichselbaum
Radiation Oncology
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Ralph R. Weichselbaum
Radiation Oncology
5758 S Maryland Ave, Mc9006, 
Chicago, IL 
 (7.3 miles away)
773-702-0817
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ralph Weichselbaum is a Radiation Oncologist in Chicago, Illinois. Dr. Weichselbaum is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Fibrosarcoma, Gliomatosis Cerebri, Lung Cancer, Glioma, and Glossectomy. Dr. Weichselbaum is currently accepting new patients.

Bharat B. Mittal
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Bharat B. Mittal
Radiation Oncology
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Bharat B. Mittal
Radiation Oncology
251 E Huron St Ste LC-178, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
312-926-2520
Experience:
50+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bharat Mittal is a Radiation Oncologist in Chicago, Illinois. Dr. Mittal has been practicing medicine for over 50 years and is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Laryngeal Cancer, Mycosis Fungoides, Tongue Cancer, and Olfactory Neuroblastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Donnelly's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile